secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021491
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q1 2023 net loss $16.3M; ENLIGHTEN I Phase 3 on track for 1H 2024 data
--------------------------------------------------------------------------------

- Net loss of $16.3M for Q1 2023, compared to $11.9M in Q1 2022.
- Cash, equivalents, and short-term investments $82.7M at March 31, 2023; cash runway into mid-Q2 2024.
- ENLIGHTEN I Phase 3 trial (LYR-210, pre-surgical CRS) enrollment ongoing; data expected 1H 2024.
- ENLIGHTEN II Phase 3 trial restarted enrollment in April 2023; completion expected H2 2024.
- BEACON Phase 2 trial (LYR-220, post-surgical CRS) enrollment complete; data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/0000950170-23-021491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/lyra-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer